SUNESIS PHARMACEUTICALS, INC. Patent applications |
Patent application number | Title | Published |
20140378505 | SNS-595 AND METHODS OF USING THE SAME - The present invention relates to SNS-595 and of treating cancer using the same. | 12-25-2014 |
20140275547 | STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION - Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles. | 09-18-2014 |
20140205680 | METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OX- O-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID FOR TREATMENT OF CANCER - Methods of treating, preventing or managing cancer, including certain leukemias are disclosed. The methods encompass the administration of enantiomerically pure (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed. | 07-24-2014 |
20140205679 | METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OX- O-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID IN COMBINATION THERAPY - Methods of treating, preventing or managing cancers are disclosed. The methods encompass the administration of SNS-595 in combination with a second active agent. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cisplatin, carboplatin, gemcitabine or a combination thereof. | 07-24-2014 |
20140171660 | METHOD OF PREPARING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OX- O-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID - Methods of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid are disclosed. Also provided are pharmaceutical compositions comprising (+)-1,4-dihydro-7-[(3S,45)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid, and methods of treatment using such compositions. | 06-19-2014 |
20130345192 | HETEROCYCLIC TYROSINE KINASE INHIBITORS - The present invention provides compounds useful as inhibitors of Tec family kinases, compositions thereof, and methods of using the same. | 12-26-2013 |
20130244967 | SNS-595 AND METHODS OF USING THE SAME - The present invention relates to SNS-595 and methods of treating cancer using the same. | 09-19-2013 |
20130102559 | METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OX- O-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID FOR TREATMENT OF ANTECEDENT HEMATOLOGIC DISORDERS - Methods of treating, preventing or managing antecedent hematologic disorders, such as myelodysplastic syndrome, including chronic myelomonocytic leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cytarabine. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed. | 04-25-2013 |
20130065858 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS - The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases. | 03-14-2013 |
20120157443 | BRUTON'S TYROSINE KINASE INHIBITORS - The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same. | 06-21-2012 |
20120157442 | HETEROARYL BTK INHIBITORS - The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same. | 06-21-2012 |
20120077711 | Novel Ligands and Libraries of Ligands - The present invention provides compounds and libraries of compounds having formula (I): | 03-29-2012 |
20110293745 | AURORA KINASE INHIBITORS - The present invention provides Compound 1, solid forms thereof, compositions thereof, as Aurora kinase inhibitor for use as an oncology agent. The present invention also provides synthetic methods of preparing Compound 1 and intermediates thereto. | 12-01-2011 |
20100298342 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease - The present invention is directed to spiropiperidine compounds of formula (I) and tautomers thereof, which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved. | 11-25-2010 |
20100179123 | THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS - The present invention provides compounds having the formula: | 07-15-2010 |
20090036419 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS - The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases. | 02-05-2009 |
20090005359 | Heterocyclic Compounds Useful as RAF Kinase Inhibitors - The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases. | 01-01-2009 |